Human african trypanosomiasis (HAT) / sleeping sickness

DNDi has been focused on developing better treatments for sleeping sickness since its inception in 2003. By 2009, working closely with partners, DNDi finalized the development of nifurtimox and eflornithine (NECT), a simpler, safer treatment for the second stage of the most common form of the disease. In 2018, DNDi and its partners delivered fexinidazole, a paradigm-changing simple oral treatment for both stages of the disease that can be taken at home. The clinical development of fexinidazole was finalized in late 2022 with the clinical study report for Phase IIIb open-label trial.